Pancreatic cancer is an ailment in which malignant (cancerous) cells
form in tissues of the pancreas. The pancreas is an organ that lies
between the stomach and the spine. The pancreas produces
stomach-related juices and hormones that direct glucose. Exocrine
pancreas cells deliver stomach-related juices, while endocrine
pancreas cells produce hormones. The pancreatic cancer generates
mostly in exocrine cells. Globally, pancreatic cancer is the 12th
most common cancer in men and the 11th most common cancer in women.
Report Overview @
https://www.transparencymarketresearch.com/pancreatic-cancer-diagnostics-market.html
Early pancreatic cancer causes a few side-effects, a large number of
which are indistinct. Since signs and indications of pancreatic
cancer are mostly mistaken for less serious digestive disorders, the
infection is only sometimes distinguished before it has spread to
adjacent tissues or removed organs through the blood stream or
lymphatic system. The pancreatic cancer spreads in five stages. From
stage 0 to stage 5, cancerous cells spread in different tissue, blood
stream, and lymphatic system. General symptoms of the pancreatic
cancer include jaundice, pain in upper or middle abdomen, unexplained
body weight, fatigue, and loss of appetite.
Based on treatment, the pancreatic cancer diagnostics market can be
classified into surgery, chemotherapy, radiation therapy, and
targeted therapy. Surgery and chemotherapy segments are expanding at
a more rapid pace than radiation therapy and targeted therapy
segments. This is due to the better clinical outcome and it offers
realistic chances for cure. Based on test, the market has been
segmented into imaging test, biopsy, and blood test. The imaging test
segment holds the maximum market share, as imaging tests offer
detection of cancer at an early stage. Based on end–user, the
market has been segmented into hospitals, clinics, and research
institutes. The hospitals segment is expanding at a rate higher than
the other two segments.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32222
This growth is attributable to preference by patients to obtain
complete treatment and availability of advanced tools and expertise.
The market for pancreatic cancer diagnostics is expanding, due to
increase in the consumption of alcohol and tobacco and changes in
lifestyle. Moreover, high adoption of premium-priced drugs such as
Abraxane injection and Gemzar to treat the pancreatic cancer boost
the market. However, factors such as difficulty in diagnosis during
the early stages, limited treatment options (especially when the
disease has spread to other parts of the body), low success rates of
clinical trials for anti-cancer drugs, and high cost associated with
the treatment hamper the pancreatic cancer diagnostics market.
Geographically, the pancreatic cancer diagnostics market has been
segmented into regions such as North America, Europe, Asia Pacific,
and Middle East & Africa. North America hold the leading market
share, due to associated with excessive alcohol use and gallstones.
As estimated by SEER, 46,420 new pancreatic cancer cases were
reported in the U.S. in 2014.
Well-established health care
infrastructure, demand for premium-priced drugs, and rapid marketing
approvals of drugs boost the market in Europe. Multinational
companies are making significant investments in developing economies
in Asia to penetrate the untapped markets. Growing habit of smoking,
improper diet, and genetics are major factors that drive the market
in India. The Rest of the World includes the Middle East, Africa
Changes in the medical practice, availability of a wide range of
products, and increasing adoption of targeted therapies are likely to
drive the pancreatic cancer diagnostics market in the region during
the forecast period.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=32222<ype=S
Some of the key players operating in the pancreatic cancer
diagnostics market are Amgen, Inc., Celgene Corporation, Clovis
Oncology, Inc., Eli Lilly and Company, Novartis AG, and Threshold
Pharmaceuticals, Inc.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment